News

MRNA Q2 Deep Dive: Revenue Beat Overshadowed by Lower Guidance and Cost Cuts

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...
AlterNet on MSN57mOpinion

Trump's catastrophic collapse is real — and he may take us all down with him | Opinion

There’s no sugarcoating the truth: as fascism‘s grip tightens under Donald Trump and the GOP, America’s government no longer ...